Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

FOLD Amicus Therapeutics

Trading 03-02 10:39:24 EST

14.35

-0.02

-0.17%

High14.36	Low14.34	Vol765.26K
Open14.34	D1 Closing14.37	Amplitude0.10%
Mkt Cap4.50B	Tradable Cap4.46B	Total Shares314.00M
T/O10.98M	T/O Rate0.25%	Tradable Shares311.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"FOLD","market":"US","secType":"STK","nameCN":"Amicus Therapeutics","latestPrice":14.345,"timestamp":1772465961483,"preClose":14.37,"halted":0,"volume":765257,"delay":0,"changeRate":-0.0017397355601947515,"floatShares":311000000,"shares":314000000,"eps":-0.087915,"marketStatus":"Trading","change":-0.025,"latestTime":"03-02 10:39:24 EST","open":14.34,"high":14.355,"low":14.34,"amount":10980357.407116,"amplitude":0.001044,"askPrice":14.35,"askSize":26261,"bidPrice":14.34,"bidSize":43362,"shortable":3,"etf":0,"ttmEps":-0.087915,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1772485200000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1180584000000,"exchange":"NASDAQ","adjPreClose":14.37,"preHourTrading":{"tag":"盘前","latestPrice":14.36,"preClose":14.37,"latestTime":"09:29 EST","volume":3493,"amount":50125.73762,"timestamp":1772461799999,"change":-0.01,"changeRate":-0.000696,"amplitude":0.00128},"postHourTrading":{"tag":"盘后","latestPrice":14.35,"preClose":14.37,"latestTime":"18:15 EST","volume":258316,"amount":3712190.2911,"timestamp":1772234156580,"change":-0.02,"changeRate":-0.001392,"amplitude":0.001392},"volumeRatio":1.350769,"impliedVol":0.2795,"impliedVolPercentile":0.1514},"requestUrl":"/m/hq/s/FOLD/wiki","defaultTab":"wiki","newsList":[{"id":"2614954230","title":"BioMarin Deal Reshapes Amicus Therapeutics Outlook For Growth And Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2614954230","media":"Simply Wall St.","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614954230?lang=en_us&edition=fundamental","pubTime":"2026-02-26 13:26","pubTimestamp":1772083574,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical has entered into a definitive agreement to acquire Amicus Therapeutics.\nThe deal marks a major change for Amicus Therapeutics and its commercial portfolio.\nThe transaction is viewed as a material event for shareholders and the wider biotechnology sector.\n\nFor investors watching Amicus Therapeutics, NasdaqGM:FOLD, the new acquisition agreement with BioMarin comes at a time when the stock is trading at $14.34. Over the past year, the share price return of 58.8% and...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/biomarin-deal-reshapes-amicus-therapeutics-outlook-for-growt","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/biomarin-deal-reshapes-amicus-therapeutics-outlook-for-growt","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FOLD","BK4139","LU2065171402.SGD","LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD"],"gpt_icon":0},{"id":"2613737176","title":"BioMarin Q4 net income swings to a GAAP net loss of USD 47 million on 17% revenue growth to USD 875 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613737176","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613737176?lang=en_us&edition=fundamental","pubTime":"2026-02-24 05:08","pubTimestamp":1771880902,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioMarin Pharmaceutical Inc. published the original content used to generate this news brief via PR Newswire  on February 23, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260223:nNDL1336SG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BMRN","IE0002270589.USD","BK4139","IE00B19Z3581.USD","LU2065171402.SGD","FOLD","LU2065169927.USD","IE00B7SZLL34.SGD","LU2065170008.USD","BK4566","IE00B19Z3B42.SGD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2613724712","title":"Amicus Therapeutics Q4 Profit Print Tests Bullish Profitability Narratives","url":"https://stock-news.laohu8.com/highlight/detail?id=2613724712","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613724712?lang=en_us&edition=fundamental","pubTime":"2026-02-23 07:28","pubTimestamp":1771802907,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (FOLD) closed out FY 2025 with Q4 revenue of US$185.2 million and basic EPS of US$0.01, alongside net income excluding extra items of US$1.7 million, giving investors fresh data on how the business is converting its top line into earnings. The company has seen quarterly revenue move from US$149.7 million in Q4 2024 to US$185.2 million in Q4 2025, while basic EPS shifted from US$0.05 to US$0.01 over the same period, creating a mixed picture on profitability trends. With...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/amicus-therapeutics-q4-profit-print-tests-bullish-profitabil","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/amicus-therapeutics-q4-profit-print-tests-bullish-profitabil","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","LU2065171402.SGD","BK4112","FOLD","LU2065171311.SGD","BLSG","LU2065170008.USD","LU2065169927.USD","BLSX"],"gpt_icon":0},{"id":"2613229452","title":"Legal Challenges Loom Over Amicus–BioMarin Merger, Raising Execution and Shareholder Risks","url":"https://stock-news.laohu8.com/highlight/detail?id=2613229452","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613229452?lang=en_us&edition=fundamental","pubTime":"2026-02-22 14:05","pubTimestamp":1771740344,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (FOLD) has disclosed a new risk, in the Litigation & Legal Liabilities category. He observes that additional stockholder and cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/legal-challenges-loom-over-amicus-biomarin-merger-raising-execution-and-shareholder-risks?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/legal-challenges-loom-over-amicus-biomarin-merger-raising-execution-and-shareholder-risks?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2065171311.SGD","BK4139","LU2065171402.SGD","LU2065170008.USD","FOLD","LU2065169927.USD"],"gpt_icon":0},{"id":"2613975322","title":"Amicus Q4 revenue beats estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2613975322","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613975322?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:10","pubTimestamp":1771621816,"startTime":"0","endTime":"0","summary":"Amicus Q4 revenue beats estimatesOverviewBiotechnology firm's Q4 revenue rose 24%, beating analyst expectationsAdjusted EPS for Q4 beat analyst expectationsOutlookCompany will not provide financial gu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nL1N3ZG0ZF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD","LU2065169927.USD","LU2065171402.SGD","BK4139","LU2065170008.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2613929735","title":"Amicus Therapeutics Q4 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $185.213M Beat $179.764M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2613929735","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613929735?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:05","pubTimestamp":1771621523,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (NASDAQ:FOLD) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.08 by 19.05 percent. This is a 11.11 percent increase over earnings of $0.09 per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50764490/amicus-therapeutics-q4-adj-eps-0-10-beats-0-08-estimate-sales-185-213m-beat-179-764m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Amicus Therapeutics Q4 Adj. EPS $0.10 Beats $0.08 Estimate, Sales $185.213M Beat $179.764M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD"],"gpt_icon":0},{"id":"2613920742","title":"BRIEF-Amicus Therapeutics Q4 Revenue USD 185.2 Million Vs. IBES Estimate USD 180.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613920742","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613920742?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621305,"startTime":"0","endTime":"0","summary":"BRIEF-Amicus Therapeutics Q4 Revenue USD 185.2 Million Vs. IBES Estimate USD 180.7 Million\n\n\nFeb 20 (Reuters) - Amicus Therapeutics Q4 net income USD 1.7 million.\n\nQ4 EPS USD 0.01","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nPLXA23EAE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU2065171402.SGD","LU2065169927.USD","FOLD","LU2065171311.SGD","LU2065170008.USD"],"gpt_icon":0},{"id":"2613292071","title":"Amicus FY 2025 Pombiliti + Opfolda sales rose 57% to USD 34.97M","url":"https://stock-news.laohu8.com/highlight/detail?id=2613292071","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613292071?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621287,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics reported FY 2025 total revenues of USD 634.2 million, up 20% year over year, with Q4 total revenues of USD 185.2 million, up 24%. FY 2025 Galafold net product sales were USD 521.7 million, up 14%, and Pombiliti plus Opfolda net product sales were USD 112.5 million, up 60%. FY 2025 GAAP net loss attributable to common stockholders was USD 27.1 million, compared with a GAAP net loss in FY 2024, while Q4 2025 GAAP net income was USD 1.69 million. FY 2025 cash, cash equivalents, and marketable securities were USD 293.5 million at Dec. 31, 2025, up from the prior year. On corporate updates, Amicus said it has a definitive agreement to be acquired by BioMarin for USD 14.50 per share in an all-cash transaction valued at about USD 4.8 billion, expected to close in Q2 2026 subject to conditions; the FTC granted early termination of the HSR waiting period on Feb. 11, 2026. Amicus also highlighted new Fabry and Pompe disease data presented at the 22nd Annual WORLD Symposium, i","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nNDL2JN7Nd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","SG9999014013.SGD","IE00B19Z3B42.SGD","LU2095319765.USD","FOLD","SG9999014005.SGD","BK4112","LU2065170008.USD","BK4566","BK4139","IE00BKPKM429.USD","LU2210150020.SGD","SG9999014021.USD","LU0314104364.USD","IE0002270589.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","SG9999014039.USD","BK4588","LU2210149790.SGD","IE00B7SZLL34.SGD","IE00B19Z3581.USD","LU2065171311.SGD","IE00B3QW5Z07.USD","LU2065169927.USD","NDAQ","BK4585","BMRN"],"gpt_icon":0},{"id":"2613292019","title":"Amicus Therapeutics Q4 Revenue USD 185.2 Million VS. Ibes Estimate USD 180.7 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2613292019","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613292019?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621261,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260220:nPLXA23EAE:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","LU2065171402.SGD","FOLD","LU2065171311.SGD","LU2065170008.USD","LU2065169927.USD"],"gpt_icon":0},{"id":"2613292028","title":"Press Release: Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2613292028","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613292028?lang=en_us&edition=fundamental","pubTime":"2026-02-21 05:01","pubTimestamp":1771621260,"startTime":"0","endTime":"0","summary":"2025 Total Revenue of $634M, up 17% Year-over-Year at CER. Proposed Acquisition by BioMarin Expected to Close in Q2 2026, Subject to Closing Conditions. PRINCETON, N.J., Feb. 20, 2026  -- Amicus Therapeutics , a leading, global biotechnology company with a clear and compelling mission to develop and deliver transformative medicines for people living with rare diseases, today announced financial results for the full year ended December 31, 2025.-- Total revenues for the full year 2025 were $634.2 million, reflecting. strong operational growth measured at constant exchange rates 1 of. revenues were $185.2 million up 24%, or 20% at CER1.Three Months Ended  Year over Year %    Ended December    Year over Year %. -- Galafold  net product sales for the full year 2025 were. $521.7 million, representing a year-over-year increase of 14%, or 12% at. driven by continued commercial execution in all markets, net new patient. sales for the full year 2025 were $112.5 million, representing a. year-ove","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4604","LU2065169927.USD","03160","BK4022","LU2065170008.USD","BK4555","BK4585","LU2065171402.SGD","BK4099","FOLD","TM","BK4232","BK4588","LU2065171311.SGD","R"],"gpt_icon":0},{"id":"2612740965","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2612740965","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612740965?lang=en_us&edition=fundamental","pubTime":"2026-02-19 19:00","pubTimestamp":1771498800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Cushman & Wake.                                   4Q       .54    7:00 AM","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AGM","CEG","EXR","CHH","AXTI","EWTX","FNF","AMH","CQP","AGM.A","APPN","BBDC","CPRT","ALRM","DE","FIVN","ED","ACH","CNP","ARDX","CARG","AKAM","FOLD","CTO","COLD","EIG","EDIT","ASIC","EGO","EPAM","FND","CGAU","CWST","DTM","FIX","BALY","EVRG","CCCC","CENX","ALIT","ETSY","AMN","BABA","BAND","AG","DAVA","DBX","CWK","CVE","CC"],"gpt_icon":1},{"id":"2612449380","title":"Top News Today: Stocks Rise, Oil Falls as Iran Tensions Subside","url":"https://stock-news.laohu8.com/highlight/detail?id=2612449380","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612449380?lang=en_us&edition=fundamental","pubTime":"2026-02-18 05:36","pubTimestamp":1771364160,"startTime":"0","endTime":"0","summary":"TREASURYS: Treasury yields finished mixed as traders digested recent economic data.COMMODITIES: Oil prices fell on signs of progress in negotiations between the U.S. and Iran.Warner Reopens Talks With Paramount After Sweetened Offer. Warner Bros. Discovery said Tuesday it will restart deal talks with Paramount, setting the stage for a potential bidding war with its preferred suitor Netflix.The move comes after Paramount last week sweetened its all-cash $77.9 billion hostile offer for all of Warner Discovery, including its cable channels CNN and TNT.Consumer prices rose 2.4% in January from a year earlier, cooler than December's 2.7% increase. Meanwhile, the U.S. economy added a surprising 130,000 jobs in January, while the unemployment rate ticked down slightly to 4.3%.\"We saw some progress, but we saw some warning, I want to get some more information,\" he said in an interview on CNBC Tuesday.\"Our MASSIVE Trade Deal with Japan has just launched","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4141","CARV","LU0719512351.SGD","LU1244550577.SGD","LU2237443549.SGD","ADI","BK4195","FOLD","LU0312595415.SGD","LU2237443978.SGD","CRL","LU0390134368.USD","LU0724618433.USD","LU1670711040.USD","LU0128526141.USD","LU2275660780.HKD","LU2065170008.USD","LU1670710661.SGD","IE0009356076.USD","LU2237443382.USD","BK4211","LU0029874061.USD","CAR","BK4022","LU1815336760.USD","LU2133065610.SGD","BK4530","LU2458330243.SGD","LU2298322129.HKD","BK4605","LU2237443622.USD","LU1992135399.USD","LU2272731782.SGD","LU0077335932.USD","BK4512","BLFY","LU1670710588.SGD","LU1670711123.USD","LU2458330169.SGD","LU1244550221.USD","LU1992135472.HKD","LU0757428866.USD","LU2360107325.USD","LU2065171402.SGD","LU2237438978.USD","BK4585","LU0109392836.USD","LU1803068979.SGD","LU0082616367.USD","LU0314104364.USD"],"gpt_icon":0},{"id":"2611977093","title":"BioMarin Closes $850 Million Senior Unsecured Notes Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2611977093","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2611977093?lang=en_us&edition=fundamental","pubTime":"2026-02-13 05:08","pubTimestamp":1770930506,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical Inc. has closed its previously announced private offering of $850 million in 5.500% senior unsecured notes due 2034. The notes were issued at 100% of their principal amount. The proceeds from this offering, along with borrowings under a new $2 billion senior secured term loan B facility, an $800 million senior secured term loan A facility, and cash on hand, will be used to fund BioMarin's pending acquisition of Amicus Therapeutics, Inc. and related expenses. The notes are subject to a special mandatory redemption if the acquisition is not completed by December 19, 2026, or upon certain other events. The notes are jointly and severally guaranteed by certain BioMarin subsidiaries and, following the acquisition, by Amicus and some of its subsidiaries.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational pu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260212:nNDL9jfmJB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2065171402.SGD","BMRN","IE0002270589.USD","LU2065170008.USD","FOLD","IE00B19Z3581.USD","LU2065171311.SGD","IE00B7SZLL34.SGD","BK4139","BK4566","IE00B19Z3B42.SGD","LU2065169927.USD"],"gpt_icon":0},{"id":"2608793038","title":"Amicus Therapeutics Unveils New Clinical Data for Galafold and Pombiliti + Opfolda in Fabry and Pompe Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2608793038","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608793038?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:01","pubTimestamp":1770123674,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics Inc. has announced the presentation of new data from clinical and real-world studies of Galafold  for Fabry disease and POMBILITI  + OPFOLDA  for late-onset Pompe disease at the 22nd Annual WORLDSymposium 2026. The new data include results from an open-label study evaluating the safety, pharmacokinetics, pharmacodynamics, and efficacy of migalastat in pediatric patients with Fabry disease, as well as analyses of real-world effectiveness of migalastat versus enzyme replacement therapy in treatment-nave patients with Fabry disease. Additional presentations cover structured methodologies for evaluating patient-reported outcomes and clinical characterization of Fabry disease using Swedish national registers. These results are being presented during the conference.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL7BJKt8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD","LU2065171402.SGD","LU0314104364.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","LU2095319765.USD","LU2065170008.USD","NDAQ","SG9999014039.USD","LU2210150020.SGD","BK4588","BK4139","LU2065169927.USD","LU2210149790.SGD","SG9999014021.USD","LU2065171311.SGD","BK4112","IE00B64PRP62.GBP","SG9999014013.SGD","BK4585","IE00BKPKM429.USD","SG9999014005.SGD"],"gpt_icon":0},{"id":"2608087939","title":"Amicus Therapeutics präsentiert neue Langzeitdaten zu Galafold und Pombiliti + Opfolda","url":"https://stock-news.laohu8.com/highlight/detail?id=2608087939","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608087939?lang=en_us&edition=fundamental","pubTime":"2026-02-03 21:01","pubTimestamp":1770123674,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics Inc. hat die Prsentation neuer Daten aus klinischen und Real-World-Studien zu Galafold  für die Behandlung der Fabry-Krankheit sowie zu POMBILITI  + OPFOLDA  für die spte Form der Pompe-Krankheit angekündigt. Die Ergebnisse werden auf dem 22. jhrlichen WORLDSymposium 2026 vorgestellt.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDLpyM6M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","LU2210149790.SGD","BK4585","SG9999014013.SGD","SG9999014005.SGD","SG9999014039.USD","LU2065171402.SGD","BK4139","NDAQ","BK4112","LU2065169927.USD","IE00B3QW5Z07.USD","FOLD","LU2095319765.USD","LU2065170008.USD","IE00B64PRP62.GBP","LU0314104364.USD","LU2210150020.SGD","LU2065171311.SGD","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR"],"gpt_icon":0},{"id":"2607068258","title":"Is It Time To Reassess Amicus Therapeutics (FOLD) After Last Year’s 48.9% Gain?","url":"https://stock-news.laohu8.com/highlight/detail?id=2607068258","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607068258?lang=en_us&edition=fundamental","pubTime":"2026-01-30 04:29","pubTimestamp":1769718554,"startTime":"0","endTime":"0","summary":"If you are wondering whether Amicus Therapeutics at around US$14.28 is offering good value today, the key is to look past the share price and focus on what the underlying valuation signals are telling you.\nThe stock has been relatively flat over the past month with a 0.2% return, but the 48.9% return over the last year contrasts with a small 0.5% decline in the last 7 days and a modest 0.1% return year to date, which can change how investors see both its potential and its risks.\nRecent...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/is-it-time-to-reassess-amicus-therapeutics-fold-after-last-y","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-fold/amicus-therapeutics/news/is-it-time-to-reassess-amicus-therapeutics-fold-after-last-y","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["FOLD","DCF","LU2065170008.USD","LU2065171402.SGD","BK4139","LU2065169927.USD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2606620980","title":"Amicus Therapeutics: Solid Fundamentals but Limited Upside Amid BioMarin Takeover, Justifying Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2606620980","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606620980?lang=en_us&edition=fundamental","pubTime":"2026-01-27 15:55","pubTimestamp":1769500528,"startTime":"0","endTime":"0","summary":"Ritu Baral, an analyst from TD Cowen, maintained the Hold rating on Amicus. The associated price target remains the same with $14.50. Ritu Baral ha...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/amicus-therapeutics-solid-fundamentals-but-limited-upside-amid-biomarin-takeover-justifying-hold-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/amicus-therapeutics-solid-fundamentals-but-limited-upside-amid-biomarin-takeover-justifying-hold-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["FOLD"],"gpt_icon":0},{"id":"2605090446","title":"Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605090446","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605090446?lang=en_us&edition=fundamental","pubTime":"2026-01-23 08:27","pubTimestamp":1769128051,"startTime":"0","endTime":"0","summary":"Bradley L. Campbell, President and CEO of Amicus Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Amicus Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260123:nNDL783nyB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","FOLD","LU2065169927.USD","LU2065170008.USD","LU2065171402.SGD","LU2065171311.SGD"],"gpt_icon":0},{"id":"2605491110","title":"Amicus Therapeutics Cut to Hold From Buy by Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2605491110","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605491110?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:25","pubTimestamp":1769088300,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/FOLD/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 22, 2026 08:25 ET (13:25 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["FOLD","LU2065170008.USD","LU2065171311.SGD","LU2065171402.SGD","LU2065169927.USD","BK4139"],"gpt_icon":0},{"id":"2605910496","title":"Jefferies Downgrades Amicus Therapeutics to Hold From Buy, Adjusts Price Target to $14.50 From $16","url":"https://stock-news.laohu8.com/highlight/detail?id=2605910496","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605910496?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:39","pubTimestamp":1769085558,"startTime":"0","endTime":"0","summary":"Amicus Therapeutics (FOLD) has an average rating of hold and mean price target of $14.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from majo","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["FOLD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.amicusrx.com","stockEarnings":[{"period":"1week","weight":0.0021},{"period":"1month","weight":0.0063},{"period":"3month","weight":0.4471},{"period":"6month","weight":0.8933},{"period":"1year","weight":0.5637},{"period":"ytd","weight":0.0091}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. The company also develops AT-GAA, a novel treatment paradigm for Pompe disease; and enzyme replacement therapies for Pompe diseases. It has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. The company was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.06136},{"month":2,"riseRate":0.526316,"avgChangeRate":-0.038415},{"month":3,"riseRate":0.555556,"avgChangeRate":0.039527},{"month":4,"riseRate":0.388889,"avgChangeRate":-0.017744},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.009978},{"month":6,"riseRate":0.631579,"avgChangeRate":0.068706},{"month":7,"riseRate":0.578947,"avgChangeRate":0.084684},{"month":8,"riseRate":0.473684,"avgChangeRate":0.040961},{"month":9,"riseRate":0.368421,"avgChangeRate":-0.011223},{"month":10,"riseRate":0.315789,"avgChangeRate":-0.067456},{"month":11,"riseRate":0.578947,"avgChangeRate":0.061605},{"month":12,"riseRate":0.526316,"avgChangeRate":-0.004164}],"exchange":"NASDAQ","name":"Amicus Therapeutics","nameEN":"Amicus Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Amicus Therapeutics(FOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Amicus Therapeutics,FOLD,Amicus Therapeutics股票,Amicus Therapeutics股票老虎,Amicus Therapeutics股票老虎国际,Amicus Therapeutics行情,Amicus Therapeutics股票行情,Amicus Therapeutics股价,Amicus Therapeutics股市,Amicus Therapeutics股票价格,Amicus Therapeutics股票交易,Amicus Therapeutics股票购买,Amicus Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Amicus Therapeutics(FOLD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Amicus Therapeutics(FOLD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction